ArticleDiscover oncology2025
N(6)-methyladenosine modification of ADGRA3 by ZC3H13 suppresses papillary thyroid cancer cell malignancy by inactivating the PI3K/Akt/mTOR signaling pathway.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundN(6)-methyladenosine (m
methodsThe levels of ADGRA3 and ZC3H13 in PTC were analyzed by quantitative reverse-transcription polymerase chain reaction and Western blotting. Cell functional assays, including cell counting kit-8, wound-healing assay, and Transwell assay, were performed to assess PTC malignancy. The levels of the migration and invasion markers were detected through Western blotting. The PI3K/Akt/mTOR pathway was examined through Western blotting for pathway-associated markers. MeRIP and RNA stability assays were utilized to evaluate the regulatory effect of ZC3H13 on ADGRA3.
resultsADGRA3 was downregulated in PTC samples. ADGRA3 overexpression attenuated PTC cells to proliferate, migrate, and invade through the inhibition of the PI3K/Akt/mTOR pathway. ZC3H13 enhanced ADGRA3 mRNA stability by mediating m
conclusionThis study uncovers a novel regulatory mechanism in which ZC3H13-mediated m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.